VKTX - Viking Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $93.60 DETAILS

Stock News

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

Aug 17, 2026 08:12 AM • zacks.com

2 GLP-1 Stocks That Could Double Your Money by 2031

They are fairly risky, but their potential upside is massive.

Aug 16, 2026 12:00 PM • fool.com

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

Aug 08, 2026 11:30 AM • fool.com

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) by 18.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 542,516 shares of the biotechnology company's stock after buying an additional 82,941 shares during the period. Dimensional Fund

Aug 07, 2026 11:30 PM • defenseworld.net

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Viking Therapeutics (VKTX) maintains a Hold rating as competitive pressures intensify in the GLP-1 obesity drug space and key data catalysts approach. VKTX's lead asset VK2735 is in large Phase 3 VANQUISH trials, but efficacy expectations are high, and prior data is limited to a small, short Phase 2 study. A pivotal Q3 catalyst is the maintenance dosing study for VK2735; results could drive price volatility and influence funding needs amid high cash burn.

Aug 07, 2026 11:13 AM • seekingalpha.com

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits.

Aug 06, 2026 06:21 AM • fool.com

VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs

Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.

Jul 30, 2026 09:35 AM • zacks.com

Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript

Jul 29, 2026 06:53 PM • seekingalpha.com

Viking Therapeutics Q2 Earnings Call Highlights

Viking Therapeutics NASDAQ: VKTX reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735, through Phase III development in injectable and planned oral formulations.

Jul 29, 2026 05:04 PM • marketbeat.com

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash Position of $502 Million -- SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2026, and provided an update on its clinical pipeline and other corporate developments.

Jul 29, 2026 12:05 PM • prnewswire.com

3 Biotech Stocks With Massive Upside to Buy Before August Starts

Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.

Jul 29, 2026 04:00 AM • 247wallst.com

Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case

Viking Therapeutics has a promising pipeline candidate in late-stage studies. Positive results from ongoing phase 3 trials could send the stock soaring.

Jul 28, 2026 01:00 PM • fool.com

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Jul 28, 2026 07:10 AM • zacks.com

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Jul 28, 2026 06:31 AM • zacks.com

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.

Jul 23, 2026 02:46 PM • zacks.com

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Ms. Gemmell is a highly experienced executive and board advisor with over 25 years of leadership experience across healthcare, digital health, and commercialization.

Jul 23, 2026 03:05 AM • prnewswire.com

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter of 2026 after the market close on Wednesday, July 29, 2026.

Jul 22, 2026 12:05 PM • prnewswire.com

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Jul 21, 2026 12:41 PM • prnewswire.com (Hide legal announcements)

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.

Jul 18, 2026 11:45 AM • fool.com

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes.

The key trial results for VK2735 are still years away. There are some useful indicative results coming from a phase 1 maintenance trial over the next six or so months.

Jul 18, 2026 05:30 AM • fool.com